Abstract:Purpose: This systematic review evaluates the safety and efficacy of ocular gene therapy using adeno-associated virus (AAV). Methods: MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov were searched systematically for controlled or non-controlled interventional gene therapy studies using key words related to retinal diseases, gene therapy, and AAV vectors. The primary outcome measure was safety, based on ocular severe adverse events (SAEs). Secondary outcome measures evaluated efficacy of the therapy based on best corrected visual acuity (BCVA) and improvements in visual sensitivity and systemic involvement following ocular delivery. Pooling was done using a DerSimonian Laird random effects model. Risk of bias was assessed using the Cochrane Risk of Bias Tool, version 1. Results: Our search identified 3548 records. Of these, 80 publications met eligibility criteria, representing 28 registered clinical trials and 5 postmarket surveillance studies involving AAV gene therapy for Leber congenital amaurosis (LCA), choroideremia, Leber hereditary optic neuropathy (LHON), age-related macular degeneration (AMD), retinitis pigmentosa (RP), X-linked retinoschisis, and achromatopsia. Overall, AAV therapy vectors were associated with a cumulative incidence of at least one SAE of 8% (95% confidence intervals [CIs] of 5% to 12%). SAEs were often associated with the surgical procedure rather than the therapeutic vector itself. Poor or inconsistent reporting of adverse events (AEs) were a limitation for the meta-analysis. The proportion of patients with any improvement in BCVA and visual sensitivity was 41% (95% CIs of 31% to 51%) and 51% (95% CIs of 31% to 70%), respectively. Systemic immune involvement was associated with a cumulative incidence of 31% (95% CI = 21% to 42%). Conclusions: AAV gene therapy vectors appear to be safe but the surgical procedure required to deliver them is associated with some risk. The large variability in efficacy can be attributed to the small number of patients treated, the heterogeneity of the population and the variability in dosage, volume, and follow-up. Translational relevance: This systematic review will help to inform and guide future clinical trials.

Adeno-Associated Virus Mediated Sod Gene Therapy Protects the Retinal Ganglion Cells from Chronic Intraocular Pressure Elevation Induced Injury Via Attenuating Oxidative Stress and Improving Mitochondrial Dysfunction in A Rat Model

Effects of antioxidant gene therapy on retinal neurons and oxidative stress in a model of retinal ischemia/reperfusion.

The Effect of A2AReceptor Antagonist on Microglial Activation in Experimental Glaucoma

Scaav2-Mediated C3 Transferase Gene Therapy in a Rat Model with Retinal Ischemia/Reperfusion Injuries

Long-Term Rescue Of Rat Retinal Ganglion Cells And Visual Function By Aav-Mediated Bdnf Expression After Acute Elevation Of Intraocular Pressure

AAV-NDI1 Therapy Provides Significant Benefit to Murine and Cellular Models of Glaucoma

Rescue of retinal ganglion cells in optic nerve injury using cell-selective AAV mediated delivery of SIRT1

Hydrogen sulfide supplement attenuates the apoptosis of retinal ganglion cells in experimental glaucoma.

NMNAT2 is Downregulated in Glaucomatous RGCs, and RGC-specific Gene Therapy Rescues Neurodegeneration and Visual Function

Timing of Antioxidant Gene Therapy: Implications for Treating Dry AMD

Group II metabotropic glutamate receptor agonist promotes retinal ganglion cell survival by reducing neuronal excitotoxicity in a rat chronic ocular hypertension model

Adeno-associated Virus-Mediated Expression of Growth-Associated Protein-43 Aggravates Retinal Ganglion Cell Death in Experimental Chronic Glaucomatous Injury.

C3 Transferase-Expressing scAAV2 Transduces Ocular Anterior Segment Tissues and Lowers Intraocular Pressure in Mouse and Monkey

Prostaglandin-based rAAV-mediated glaucoma gene therapy in Brown Norway rats

Early removal of senescent cells protects retinal ganglion cells loss in experimental ocular hypertension

Hybrid Compound SA-2 is Neuroprotective in Animal Models of Retinal Ganglion Cell Death

Effects of Antioxidant Gene Therapy on the Development of Diabetic Retinopathy and the Metabolic Memory Phenomenon

Overexpression of Optic Atrophy Type 1 Protects Retinal Ganglion Cells and Upregulates Parkin Expression in Experimental Glaucoma

Safety and Efficacy of Adeno-Associated Viral Gene Therapy in Patients With Retinal Degeneration: A Systematic Review and Meta-Analysis

Activation of adenosine A3 receptor protects retinal ganglion cells from degeneration induced by ocular hypertension

Human adipose tissue-derived stem cell extracellular vesicles attenuate ocular hypertension-induced retinal ganglion cell damage by inhibiting microglia- TLR4/MAPK/NF-κB proinflammatory cascade signaling